Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, aiming to address significant unmet needs by funding promising businesses across all stages of their development. Their strategy employs a data science-driven approach to identify breakthrough opportunities at the intersection of technology and biotechnology.
Portfolio
13
Fund Size
$3.5B
Top Stage
Series A
Last 12 Mo
1
Team
CX
Cindy Xiong
Partner
SC
Stephen C. Peterson, CFA
Partner
VD
Vishal Deshmukh, PhD
Senior Analyst
JT
Jim Tananbaum
Chief Executive Officer
Stage Distribution
Portfolio
13 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Slate Medicines | Series A | $130M | Feb 2026 |
| Thyme Care | Series B | $60M | Aug 2023 |
| CG Oncology | Series D | $105M | Aug 2023 |
| Nested Therapeutics | Series A | $90M | Oct 2022 |
| MyOme | Series B | $23M | Jun 2022 |
| Mirvie | Series B | $60M | May 2022 |
| Tasso | Growth | $100M | Dec 2021 |
| DELFI Diagnostics, Inc. | Series A | $100M | Jan 2021 |
| Kira Pharmaceuticals | Series B | $53.5M | Jan 2021 |
| Remix Therapeutics | Series A | $81M | Dec 2020 |
| Bit Bio | Series B | $41.5M | Jun 2020 |
| Cue Health | Series C | $100M | Jun 2020 |
| Pleno | Series A | $40M | — |
Top Co-Investors
RA Capital Management3 shared
ARCH Venture Partners2 shared
Goldman Sachs1 shared
Avidity Partners1 shared
ACME Capital1 shared
SoftBank Group Corp.1 shared
Sequoia Capital1 shared
Founders Fund1 shared
BlueYard Capital1 shared
Atlas Venture1 shared
The Column Group1 shared
Alexandria Venture Investments1 shared
GV (Google Ventures)1 shared
BlackRock1 shared
General Catalyst1 shared
Khosla Ventures1 shared
Mayfield Fund1 shared
OrbiMed1 shared
Menlo Ventures1 shared
Samsara BioCapital1 shared
Last updated: 1 March 2026